Eli Lilly Bets $2.4B on Dice Therapeutics’ Oral Drugs for Psoriasis and More
Eli Lilly’s acquisition of Dice Therapeutics comes eight months after the biotech reported positive data from a Phase 1 study in psoriasis. Dice develops oral small molecule drugs intended to offer alternatives to biologic drugs that are injected or infused.